JCR Pharmaceuticals (OTCMKTS:JCRRF – Get Free Report) is expected to be posting its resultson Thursday, July 30th. Analysts expect the company to post earnings of ($0.0693) per share and revenue of $61.28 million for the quarter.
JCR Pharmaceuticals Stock Performance
Shares of JCRRF opened at $3.31 on Thursday. The business’s 50-day moving average price is $3.44 and its 200-day moving average price is $3.99. JCR Pharmaceuticals has a twelve month low of $3.15 and a twelve month high of $3.31.
About JCR Pharmaceuticals
JCR Pharmaceuticals Co, Ltd. is a Japan-based biotechnology company specializing in the development, production and commercialization of plasma-derived products and regenerative medicine solutions. The company focuses on manufacturing high-purity plasma proteins, including human serum albumin, immunoglobulins and coagulation factors, to support a range of therapeutic applications in hematology, immunology and critical care settings.
In its plasma-derived business, JCR leverages state-of-the-art fractionation and purification processes to supply products such as intravenous immunoglobulin and albumin formulations.
Read More
- Five stocks we like better than JCR Pharmaceuticals
- Could Truth API Become Trump Media’s First Meaningful Revenue Driver?
- Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying
- Moog Is More Than a Missile Maker, and Wall Street Is Noticing
- A Boring Dividend Growth Strategy Becomes a Solid Defensive Play
Receive News & Ratings for JCR Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for JCR Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
